<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content

Systemic Acute Myeloid Leukemia (AML) In Vivo Screen 

Premier screen featuring a bank of superior primary patient AML models tailored to support breakthrough discoveries in Acute Myeloid Leukemia (AML) drug development. 

 

Why choose the Champions AML In Vivo Screen? 

 Clinically Relevant Models

Living & diverse bank of primary patient AML models that correlate with clinical outcomes

Pretreated PDX Models

Established from tumor biopsies from patients pretreated with latest generation therapies

Multi-omic Characterization

Clinical annotations coupled with molecular datasets and in vivo responses 

Download our Systemic AML In Vivo Screen Model List

Champions' elite AML In Vivo Screen, an advanced platform showcasing primary Acute Myeloid Leukemia (AML) models, each reflecting diverse and complex AML subtypes.

  • Includes models pretreated with advanced therapies like gilteritinib, Mylotarg, and CSF1R inhibitors, as well as those with del(7q)
  • Complete model characterization (clinical data, NGS analysis, proteomics, phospho-proteomics, and kinase activity)
  • Terminal flow cytometry analysis on peripheral blood and bone marrow
  • AML Engraftment Assessement using Champions' Standard systemic AML In Vivo engraftment panel: CD3, CD33, CD34,CD38, mCD45, hCD45, CD117, CD123, Viability Dye
  • Plasma-based Luminex available

Champions' Systemic AML In Vivo Screen

Systemic AML In vivo Screen Workflow_Oct22
Champions' Industry-leading Clinical Annotation & Multi-omic Characterization
AML In Vivo Screen: Terminal Bone Marrow Flow Cytometry Results